{"url_path":"/sec/sbfm/8-k/2026-07-20/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1402328/0001683168-26-005656-index.html","accession_number":"0001683168-26-005656","cik":"0001402328","ticker":"SBFM","issuer_name":"Sunshine Biopharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1402328/0001683168-26-005656-index.html","primary_entity_key":"0001402328","primary_entity_name":"Sunshine Biopharma Inc."},"word_count":435,"has_tables":true,"body_markdown":"**Item 1.01 Entry into a Material Definitive\nAgreement.**\n\n** **\n\nOn July 20, 2026, Sunshine Biopharma Inc. (the\n“Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Aegis Capital\nCorp. (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock, for\nan aggregate offering price of up to $4,000,000, in “at-the-market” offerings through or to the Agent, as exclusive sales\nagent. Subject to the terms and conditions of the Sales Agreement and the applicable placement notice, sales of our common stock may be\nmade by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) under the Securities\nAct of 1933, as amended (the “Securities Act”), including sales made directly on or through the Nasdaq Capital Market or any\nother existing trading market for our common stock. The Agent will receive a commission from the Company of 3.0% of the gross proceeds\nfrom the sale of any shares of common stock under the Sales Agreement, in addition to reimbursement of certain expenses.\n\n \n\nThe Company is not obligated to sell, and the Sales Agent is not obligated\nto buy or sell, any shares of common stock under the Sales Agreement. No assurance can be given that the Company will sell any shares\nof common stock under the Sales Agreement, or, if it does, as to the price or amount of shares of common stock that it sells or the dates\nwhen such sales will take place.\n\n \n\nPursuant to the Sales Agreement, the Company agreed to indemnify the\nAgent against certain liabilities, including under the Securities Act, and the Securities Exchange Act of 1934, as amended, and to contribute\nto payments that the Agent may be required to make because of such liabilities. The Company and the Agent may each terminate the Sales\nAgreement as provided in the Sales Agreement.\n\n \n\nThe shares will be issued pursuant to the Company’s\nshelf registration statement on Form S-3 (File No. 333-284142), filed with the Securities and Exchange Commission (the “SEC”)\non January 6, 2025, and declared effective on January 15, 2025, and a prospectus supplement to be filed with the SEC on July 20, 2026.\n\n \n\nThe description of the material terms of the Sales Agreement above\nis qualified in its entirety by reference to the full text of the Sales Agreement filed as Exhibit 10.1 to this report.\n\n \n\nA copy of the opinion of Hart & Hart, LLC relating to the validity\nof the shares of common stock that may be sold pursuant to the Sales Agreement is filed as Exhibit 5.1 to this report."}